Assessment cycle 2023 Q1 — page 10
Documents ratified in the 2023 Q1 assessment cycle, which ran from 1 January 2023 to 31 March 2023 and was ratified on 18 March 2023.
Documents ratified
-
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low20 May 2024 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low21 May 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low23 Jun 2023 -
Observational, phase 1 study of Ipamorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and publishes…
Very low21 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Ipamorelin in gastric emptying over as stated in the parent protocol. The Institute holds no reported…
Very low29 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low28 Apr 2024 -
Randomised crossover, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low08 Feb 2024 -
Phase 1 ascending dose, phase 1 study of Hexarelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low24 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Hexarelin in lean-mass preservation over as stated in the parent protocol. The Institute holds no reported…
Very low15 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of GHRP-2 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low17 May 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of GHRP-6 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low08 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of AOD-9604 in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low04 May 2024 -
Phase 1 ascending dose, phase 1 study of AOD-9604 in knee osteoarthritis over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low11 Sep 2023 -
Observational, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low25 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low28 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low05 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 1 study of Thymosin beta-4 in cardiovascular over as stated in the parent protocol. The Institute holds no reported…
Very low08 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of LL-37 in wound healing over as stated in the parent protocol. The Institute holds no reported primary…
Very low23 Sep 2023 -
Randomised crossover, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 Dec 2023 -
Phase 1 ascending dose, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low01 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low11 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low07 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low24 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low27 Dec 2023 -
Observational, phase 2 study of Glutathione in cognition over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Feb 2024 -
Phase 1 ascending dose, phase 1 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low25 Jul 2023 -
Phase 1 ascending dose, phase 1 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low12 Mar 2024 -
Observational, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low12 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported…
Very low21 Feb 2024 -
Phase 1 ascending dose, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low15 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low22 Mar 2024 -
Single-arm open-label, phase 2 study of Kisspeptin-10 in sexual dysfunction over open-label extension of the parent trial. The Institute holds no reported primary result…
Very low16 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Pramlintide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low09 Mar 2024 -
Phase 1 ascending dose, phase 1 study of Pramlintide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Pramlintide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low20 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of SS-31 (elamipretide) in hfpef over as stated in the parent protocol. The Institute holds no reported…
Very low11 Nov 2023 -
Single-arm open-label, phase 3 study of Semaglutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low11 Mar 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low19 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low06 Jun 2023
page 10 of 13